financetom
Business
financetom
/
Business
/
Newmont beats quarterly profit estimates on higher production
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Newmont beats quarterly profit estimates on higher production
Apr 25, 2024 5:00 AM

April 25 (Reuters) - Newmont Corp ( NEM ) beat Wall

Street estimates for first-quarter profit on Thursday, as the

world's largest gold miner benefited from strong production.

On an adjusted basis, the company posted a net income of 55

cents per share for the quarter ended March 31, compared with

the average analyst estimate of 36 cents per share, according to

LSEG data.

The Denver, Colorado-based Newmont's ( NEM ) quarterly attributable

gold production rose to 1.7 million ounces from 1.27 million

ounces a year earlier, boosted through sites acquired following

its acquisition of Australia's Newcrest A$26.2 billion ($17.09

billion) in November.

Newmont ( NEM ) also saw higher average gold price at $2,090 per

ounce in the January-March quarter from $1,906 a year earlier,

as prices of the precious metal have increased by about 8.2%.

All-in-sustaining cost for gold, an industry metric that

reflects total expenses associated with production, rose to

$1,439 per ounce of gold from $1,376 a year earlier.

($1 = 1.5328 Australian dollars)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
CAMP4 Therapeutics Prices $75 Million IPO
CAMP4 Therapeutics Prices $75 Million IPO
Oct 11, 2024
07:33 AM EDT, 10/11/2024 (MT Newswires) -- CAMP4 Therapeutics said late Thursday it priced its initial public offering of about 6.8 million common shares at $11 per share for expected gross proceeds of about $75 million. Underwriters have been granted a 30-day option to buy up to about 1 million additional shares. Shares of the biotechnology company are expected to...
Sagimet Biosciences' MASH Drug Meets Main, Secondary Goals in Phase 2b Study
Sagimet Biosciences' MASH Drug Meets Main, Secondary Goals in Phase 2b Study
Oct 11, 2024
07:41 AM EDT, 10/11/2024 (MT Newswires) -- Sagimet Biosciences ( SGMT ) said Friday that its experimental drug, denifanstat, used to treat certain metabolic-dysfunction-associated steatohepatitis patients, met its primary and secondary endpoints in a phase 2b study. The study showed that patients treated with the denifanstat showed statistically significant and clinically meaningful improvements in disease activity, MASH resolution, and fibrosis...
AGBA, Triller Complete All Steps for Merger, Awaiting Final Nasdaq Approval
AGBA, Triller Complete All Steps for Merger, Awaiting Final Nasdaq Approval
Oct 11, 2024
07:44 AM EDT, 10/11/2024 (MT Newswires) -- AGBA (AGBA) and Triller said Friday they have finalized all necessary steps for their upcoming merger, expected to be completed around Oct. 14, pending final Nasdaq approval. As part of the merger, AGBA will undergo a reverse stock split at a 4-to-1 ratio to comply with Nasdaq requirements. The reverse split will be...
Top Premarket Decliners
Top Premarket Decliners
Oct 11, 2024
07:38 AM EDT, 10/11/2024 (MT Newswires) -- Hesai Group ( HSAI ) shares fell nearly 10% pre-bell Friday, erasing Thursday's gains. SKYX Platforms ( SKYX ) shares dropped more than 9% following a 2.4% loss in the previous session. Vroom (VRM) shares were down more than 8%, adding to Thursday's 2.3% drop. Price: 4.83, Change: -0.53, Percent Change: -9.89 ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved